Adaptive Biotechnologies Corporation
NASDAQ:ADPTBiotechnology
+$0.61 today
- Market cap
- $4.61B
- Beta
- 2.15
- P/E (TTM)
- -54.5
- EPS (TTM)
- -$0.32
Volume 2.21M
Average 1.94M
ADPT Operating Cash Flow
Cash generated by the company's core business operations during the period.
Adaptive Biotechnologies CorporationNASDAQ: ADPT
Operating Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Operating cash flow declines year over year
Q2 FY2026 operating cash flow of $6.4M (cash outflow) fell 48.5% year over year, ahead of the -73.9% change in trailing-twelve-month operating cash flow. Sequentially, it fell 32.9% from the prior quarter. Over 3 fiscal years it compounded at -37.0% a year.
Context
- Operating cash flow amounted to 16.6% of revenue in FY2025, down 36.6 pp from a year earlier.
- Operating cash flow grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -48.5% holds above the trailing-twelve-month pace of -73.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (45.99M) USD
- Year-over-year change
- +51.7%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (45.99M) | +51.7% |
| FY2024 | 2024-12-31 | (95.21M) | +39.1% |
| FY2023 | 2023-12-31 | (156.32M) | +15.0% |
| FY2022 | 2022-12-31 | (183.95M) | +4.6% |
| FY2021 | 2021-12-31 | (192.73M) | — |
Operating Cash Flow vs competitors
How ADPT compares with its peers on the latest reported figures
- ADPT's LTM Jun 2026 operating cash flow of $21.01M is the smallest of the 10 companies compared; the peer median is $138.79M.
- Its year-over-year change of -73.9% is the lowest of 10, against a peer median of +4.2%.
- Operating cash flow amounts to 6.8% of revenue for ADPT, versus a peer median of 34.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $359.38M | +4.2% | — | 230.3% | |
| LTM Sep 2026 | $309.05M | +12.8% | +31.3% | 54218.6% | |
| LTM Sep 2026 | $247.8M | +45.7% | -20.7% | 18.2% | |
| LTM Mar 2026 | $208.21M | -22.3% | +21.6% | 34.9% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $189.94M | +15.3% | +62.2% | — |
| LTM Jun 2026 | $138.79M | -28.0% | +69.5% | — | |
| LTM Jun 2026 | $133.38M | -23.9% | -25.7% | 29.7% | |
| LTM Mar 2026 | $85.93M | -67.5% | -6.6% | 38.1% | |
| LTM Sep 2026 | $49.9M | +192.5% | -36.7% | 7.3% | |
| LTM Jun 2026 | $21.01M | -73.9% | -37.0% | 6.8% | |
| Peer median (excluding ADPT) | $138.79M | +4.2% | +7.5% | 34.9% | |
Competitors are the stored peer set for ADPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (207.28M) | (200.19M) | (225.25M) | (159.6M) | (59.5M) |
| Depreciation & Amortization | 13.95M | 20.92M | 22.23M | 19.26M | 17.83M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 53.61M | 51.48M |
| Change in Working Capital | (56.82M) | (71.55M) | (46.18M) | (17.45M) | (57.77M) |
| Accounts Receivables | (7.36M) | (22.65M) | 2.03M | (3.74M) | (8.65M) |
| Inventory | (5.2M) | 817K | (2.84M) | 1.94M | (998K) |
| Accounts Payables | 3.94M | 7.11M | (5.41M) | 671K | 665K |
| Other Working Capital | (48.19M) | (56.83M) | (39.97M) | (16.32M) | (48.79M) |
| Other Non-Cash Items | 57.42M | 66.87M | 92.88M | 8.97M | 1.96M |
| Operating Cash Flow | (192.73M) | (183.95M) | (156.32M) | (95.21M) | (45.99M) |
| Capital Expenditures | (61.75M) | (16.35M) | (10.7M) | (3.66M) | (2.96M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (316.54M) | (278.78M) | (429.56M) | (244.26M) | (181.71M) |
| Sales of Investments | 559.5M | 298.03M | 569.9M | 325.71M | 222.62M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 181.21M | 2.91M | 129.65M | 77.79M | 37.95M |
| Debt Repayment | 0 | 124.38M | 0 | 0 | 0 |
| Common Stock Issued | 26.72M | 7.89M | 2.25M | 241K | 30.4M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 429K | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 27.15M | 132.26M | 2.25M | 241K | 30.4M |
| Effect of Forex Changes | 0 | (260K) | (534K) | 0 | 0 |
| Net Change in Cash | 15.63M | (49.04M) | (24.97M) | (17.18M) | 22.37M |
| Free Cash Flow | (254.47M) | (200.29M) | (167.02M) | (98.88M) | (48.95M) |
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
Intrinsic Alpha fair value
Locked
Current Price
$28.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.